{"id":985,"date":"2021-04-30T09:32:24","date_gmt":"2021-04-30T09:32:24","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=985"},"modified":"2021-04-30T09:32:24","modified_gmt":"2021-04-30T09:32:24","slug":"18-apr-2021-ivermectin-a-significant-protection-of-ivermectin-as-a-prep-method-of-infection-from-sars-cov-2-was-observed","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/18-apr-2021-ivermectin-a-significant-protection-of-ivermectin-as-a-prep-method-of-infection-from-sars-cov-2-was-observed\/","title":{"rendered":"(18 Apr 2021) Ivermectin- a significant protection of Ivermectin as a PrEP method of infection from SARS-CoV-2 was observed"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p id=\"page-title\" class=\"highwire-cite-title\">Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in Healthcare Workers<\/p>\n<p class=\"\">https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.10.21255248v2<\/p>\n<p class=\"\">NCT04832945-The study began on June 29, 2020 and ended on July 26, 2020, where 713 active healthcare personnel were included for the analysis, of which 326 adhered to a weekly prophylactic program with Ivermectin for Coronavirus Disease-19 (COVID-19), designed by Grupo Rescue task force, that runs both medical centers, and 387 healthcare personnel who did not adhere to the program were assigned to the control group. A SPSS Propensity Score Matching procedure was applied in a 1:1 ratio to homogeneously evaluate the groups that were made up of 271 participants each. In 28 days of follow-up, a significant protection of Ivermectin as a PrEP method of infection from SARS-CoV-2 was observed 1.8% compared to those who did not take it 6.6%, (p-value = 0.006) and a reduction of the risk of a positive Chain Reaction of Real-Time Polymerase Transcription (RT-PCR) COVID-19 test by 74% (HR 0.26, 95% CI [0.10,0.71]). These results support the use of weekly Ivermectin as a compassionate preventive method in the healthcare personnel.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Retrospective cohort study of Ivermectin as a SARS-CoV-2 pre-exposure prophylaxis method in Healthcare Workers https:\/\/www.medrxiv.org\/content\/10.1101\/2021.04.10.21255248v2 NCT04832945-The study began on June 29, 2020 and ended on July 26, 2020, where 713 active healthcare personnel were included for the analysis, of which&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/18-apr-2021-ivermectin-a-significant-protection-of-ivermectin-as-a-prep-method-of-infection-from-sars-cov-2-was-observed\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(18 Apr 2021) Ivermectin- a significant protection of Ivermectin as a PrEP method of infection from SARS-CoV-2 was observed&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[6,4,16],"tags":[38],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/985"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=985"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/985\/revisions"}],"predecessor-version":[{"id":986,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/985\/revisions\/986"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}